BEZ235 was also reported to reduce tumor volume in a mouse model harboring PTEN loss, and the effects were enhanced when combined with AR antagonist enzalutamide, implying a potential prospect in synergy treatments cotargeting the AR, PI3K and mTOR signaling pathways in PCa [232]. Here, PIK3CD is linked to neoplasm.